{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:36:05Z","timestamp":1780104965208,"version":"3.54.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1038\/s41401-020-00527-x","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T14:03:00Z","timestamp":1601301780000},"page":"975-986","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Pristimerin protects against inflammation and metabolic disorder in mice through inhibition of NLRP3 inflammasome activation"],"prefix":"10.1038","volume":"42","author":[{"given":"Qun","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-rui","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-jun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"527_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1146\/annurev-immunol-031210-101405","volume":"29","author":"BK Davis","year":"2011","unstructured":"Davis BK, Wen H, Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011;29:707\u201335.","journal-title":"Annu Rev Immunol"},{"key":"527_CR2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/cmi.2015.95","volume":"13","author":"EK Jo","year":"2016","unstructured":"Jo EK, Kim JK, Shin DM, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol. 2016;13:148\u201359.","journal-title":"Cell Mol Immunol"},{"key":"527_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41422-020-0295-8","volume":"30","author":"S Christgen","year":"2020","unstructured":"Christgen S, Place DE, Kanneganti TD. Toward targeting inflammasomes: insights into their regulation and activation. Cell Res. 2020;30:315\u201327.","journal-title":"Cell Res"},{"key":"527_CR4","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","volume":"157","author":"M Lamkanfi","year":"2014","unstructured":"Lamkanfi M, Dixit VM. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013\u201322.","journal-title":"Cell"},{"key":"527_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/cr.2013.6","volume":"23","author":"K Mao","year":"2013","unstructured":"Mao K, Chen S, Chen M, Ma Y, Wang Y, Huang B, et al. Nitric oxide suppresses NLRP3 inflammasome activation and protects against LPS-induced septic shock. Cell Res. 2013;23:201\u201312.","journal-title":"Cell Res"},{"key":"527_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1136\/gut.2009.197822","volume":"59","author":"C Bauer","year":"2010","unstructured":"Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut. 2010;59:1192\u20139.","journal-title":"Gut"},{"key":"527_CR7","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature. 2013;493:674\u20138.","journal-title":"Nature"},{"key":"527_CR8","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357\u201361.","journal-title":"Nature"},{"key":"527_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237\u201341.","journal-title":"Nature"},{"key":"527_CR10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179\u201388.","journal-title":"Nat Med"},{"key":"527_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ni.1935","volume":"11","author":"SL Masters","year":"2010","unstructured":"Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1 beta in type 2 diabetes. Nat Immunol. 2010;11:897\u2013904.","journal-title":"Nat Immunol"},{"key":"527_CR12","doi-asserted-by":"publisher","first-page":"111822","DOI":"10.1016\/j.ejmech.2019.111822","volume":"185","author":"X Zhang","year":"2020","unstructured":"Zhang X, Xu A, Lv J, Zhang Q, Ran Y, Wei C, et al. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases. Eur J Med Chem. 2020;185:111822.","journal-title":"Eur J Med Chem"},{"key":"527_CR13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.immuni.2013.05.015","volume":"38","author":"YQ Yan","year":"2013","unstructured":"Yan YQ, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, et al. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity. 2013;38:1154\u201363.","journal-title":"Immunity"},{"key":"527_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","volume":"160","author":"YQ Yan","year":"2015","unstructured":"Yan YQ, Jiang W, Liu L, Wang XQ, Ding C, Tian ZG, et al. Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell. 2015;160:62\u201373.","journal-title":"Cell"},{"key":"527_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nm.3804","volume":"21","author":"YH Youm","year":"2015","unstructured":"Youm YH, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263\u20139.","journal-title":"Nat Med"},{"key":"527_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.immuni.2016.09.008","volume":"45","author":"C Guo","year":"2016","unstructured":"Guo C, Xie S, Chi Z, Wang D. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity. 2016;45:802\u201316.","journal-title":"Immunity"},{"key":"527_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.imbio.2013.11.003","volume":"219","author":"H Ahn","year":"2014","unstructured":"Ahn H, Kim J, Jeung EB, Lee GS. Dimethyl sulfoxide inhibits NLRP3 inflammasome activation. Immunobiology. 2014;219:315\u201322.","journal-title":"Immunobiology"},{"key":"527_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nm.3806","volume":"21","author":"RC Coll","year":"2015","unstructured":"Coll RC, Robertson AAB, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248\u201355.","journal-title":"Nat Med"},{"key":"527_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1083\/jcb.200903124","volume":"187","author":"M Lamkanfi","year":"2009","unstructured":"Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome. J Cell Biol. 2009;187:61\u201370.","journal-title":"J Cell Biol"},{"key":"527_CR20","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang H, He HB, Chen Y, Huang W, Cheng JB, Ye J, et al. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214:3219\u201338.","journal-title":"J Exp Med"},{"key":"527_CR21","doi-asserted-by":"publisher","first-page":"e8689","DOI":"10.15252\/emmm.201708689","volume":"10","author":"Y Huang","year":"2018","unstructured":"Huang Y, Rong R. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018;10:e8689.","journal-title":"EMBO Mol Med"},{"key":"527_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.4161\/auto.28374","volume":"10","author":"WJ Guo","year":"2014","unstructured":"Guo WJ, Sun Y, Liu W, Wu XX, Guo LL, Cai PF, et al. Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer. Autophagy. 2014;10:972\u201385.","journal-title":"Autophagy"},{"key":"527_CR23","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.apsb.2019.02.003","volume":"9","author":"ZL Wang","year":"2019","unstructured":"Wang ZL, Xu G, Gao Y, Zhan XY, Qin N, Fu SB, et al. Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome. Acta Pharm Sin B. 2019;9:734\u201344.","journal-title":"Acta Pharm Sin B"},{"key":"527_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04947-6","volume":"9","author":"HB He","year":"2018","unstructured":"He HB, Jiang H, Chen Y, Deng X, Jiang W, Zhou R. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. 2018;9:2550.","journal-title":"Nat Commun"},{"key":"527_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1097\/CAD.0b013e328330fd90","volume":"20","author":"A Petronelli","year":"2009","unstructured":"Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs. 2009;20:880\u201392.","journal-title":"Anticancer Drugs"},{"key":"527_CR26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ps.953","volume":"61","author":"DQ Luo","year":"2005","unstructured":"Luo DQ, Wang H, Tian X, Shao HJ, Liu JK. Antifungal properties of pristimerin and celastrol isolated from Celastrus hypoleucus. Pest Manag Sci. 2005;61:85\u201390.","journal-title":"Pest Manag Sci"},{"key":"527_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2174\/1568009616666160112105824","volume":"17","author":"BA Yousef","year":"2017","unstructured":"Yousef BA, Hassan HM, Zhang LY, Jiang ZZ. Anticancer potential and molecular targets of pristimerin: a mini-review. Curr Cancer Drug Targets 2017;17:100\u20138.","journal-title":"Curr Cancer Drug Targets"},{"key":"527_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41420-019-0208-0","volume":"5","author":"Q Zhao","year":"2019","unstructured":"Zhao Q, Liu Y, Zhong J, Bi Y, Ren Z, Li X, et al. Pristimerin induces apoptosis and autophagy via activation of ROS\/ASK1\/JNK pathway in human breast cancer in vitro and in vivo. Cell Death Discov. 2019;5:125.","journal-title":"Cell Death Discov"},{"key":"527_CR29","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fphar.2018.00292","volume":"9","author":"DS El-Agamy","year":"2018","unstructured":"El-Agamy DS, Shaaban AA, Almaramhy HH, Elkablawy S, Elkablawy MA. Pristimerin as a novel hepatoprotective agent against experimental autoimmune hepatitis. Front Pharmacol. 2018;9:292.","journal-title":"Front Pharmacol"},{"key":"527_CR30","doi-asserted-by":"publisher","first-page":"114813","DOI":"10.1016\/j.taap.2019.114813","volume":"386","author":"Q Zhao","year":"2020","unstructured":"Zhao Q, Bi Y, Zhong J, Ren ZT, Liu YX, Jia JJ, et al. Pristimerin suppresses colorectal cancer through inhibiting inflammatory responses and Wnt\/beta-catenin signaling. Toxicol Appl Pharmacol. 2020;386:114813.","journal-title":"Toxicol Appl Pharmacol"},{"key":"527_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12272-013-0054-1","volume":"36","author":"HJ Kim","year":"2013","unstructured":"Kim HJ, Park GM, Kim JK. Anti-inflammatory effect of pristimerin on lipopolysaccharide-induced inflammatory responses in murine macrophages. Arch Pharm Res. 2013;36:495\u2013500.","journal-title":"Arch Pharm Res"},{"key":"527_CR32","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.intimp.2014.06.010","volume":"21","author":"B Hui","year":"2014","unstructured":"Hui B, Yao X, Zhou QH, Wu ZY, Sheng P, Zhang LP. Pristimerin, a natural anti-tumor triterpenoid, inhibits LPS-induced TNF-alpha and IL-8 production through down-regulation of ROS-related classical NF-kappa B pathway in THP-1 cells. Int Immunopharmacol. 2014;21:501\u20138.","journal-title":"Int Immunopharmacol"},{"key":"527_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0014-2999(97)01245-4","volume":"336","author":"VM Dirsch","year":"1997","unstructured":"Dirsch VM, Kiemer AK, Wagner H, Vollmar AM. The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol. 1997;336:211\u20137.","journal-title":"Eur J Pharmacol"},{"key":"527_CR34","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12640-017-9837-3","volume":"33","author":"B Hui","year":"2018","unstructured":"Hui B, Zhang LP, Zhou QH, Hui L. Pristimerin inhibits LPS-triggered neurotoxicity in BV-2 microglia cells through modulating IRAK1\/TRAF6\/TAK1-mediated NF-kappa B and AP-1 signaling pathways in vitro. Neurotox Res. 2018;33:268\u201383.","journal-title":"Neurotox Res"},{"key":"527_CR35","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.celrep.2017.04.011","volume":"19","author":"Q Zhao","year":"2017","unstructured":"Zhao Q, Yu XJ, Zhang HW, Liu YB, Zhang XX, Wu XX, et al. RIPK3 mediates necroptosis during embryonic development and postnatal inflammation in Fadd-deficient mice. Cell Rep. 2017;19:798\u2013808.","journal-title":"Cell Rep"},{"key":"527_CR36","doi-asserted-by":"publisher","first-page":"67300","DOI":"10.18632\/oncotarget.18619","volume":"8","author":"XJ Yu","year":"2017","unstructured":"Yu XJ, Zhao Q, Zhang XX, Zhang HW, Liu YB, Wu XX, et al. Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation. Oncotarget. 2017;8:67300\u201314.","journal-title":"Oncotarget"},{"key":"527_CR37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.cell.2014.02.008","volume":"156","author":"A Lu","year":"2014","unstructured":"Lu A, Magupalli VG, Ruan J, Yin Q, Atianand MK, Vos MR, et al. Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes. Cell. 2014;156:1193\u2013206.","journal-title":"Cell"},{"key":"527_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11929","volume":"7","author":"MS Dick","year":"2016","unstructured":"Dick MS, Sborgi L, Ruhl S, Hiller S, Broz P. ASC filament formation serves as a signal amplification mechanism for inflammasomes. Nat Commun. 2016;7:11929.","journal-title":"Nat Commun"},{"key":"527_CR39","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/nature16959","volume":"530","author":"Y He","year":"2016","unstructured":"He Y, Zeng MY, Yang DH, Motro B, Nunez G. Nek7 is an essential mediator of NLRP3 activation downstream of potassium efflux. Nature. 2016;530:354\u20137.","journal-title":"Nature"},{"key":"527_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/ni.3333","volume":"17","author":"HX Shi","year":"2016","unstructured":"Shi HX, Wang Y, Li XH, Zhan XM, Tang M, Fina M, et al. NLRP3 activation and mitosis are mutually exclusive events coordinated by NEK7, a new inflammasome component. Nat Immunol. 2016;17:250\u20138.","journal-title":"Nat Immunol"},{"key":"527_CR41","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.clim.2014.09.014","volume":"155","author":"L Tong","year":"2014","unstructured":"Tong L, Nanjundaiah SM, Venkatesha SH, Astry B, Yu H, Moudgil KD. Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage. Clin Immunol. 2014;155:220\u201330.","journal-title":"Clin Immunol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00527-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T11:21:13Z","timestamp":1650540073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-020-00527-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1038\/s41401-020-00527-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]},"assertion":[{"value":"28 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}